A Phase Ib Study of the Pharmacokinetics, Safety and Efficacy of Orally Administered HQP1351 in Subjects With Refractory Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)
This study is testing an experimental oral medication called HQP1351 for patients with specific types of blood and bone marrow cancers, such as chronic myeloid leukemia and acute lymphoblastic leukemia. Researchers want to find the safest and most effective dose of this new drug to help patients who have not responded well to previous treatments.
You may be able to join if you have been diagnosed with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia and have tried at least two previous targeted cancer drugs that stopped working or caused severe side effects. There are also specific rules about when you last took other cancer treatments before starting this study.
Participants will take the experimental HQP1351 drug by mouth and have their health closely monitored by the study team to check for safety, side effects, and how the body processes the medication. The doctors will track your progress and blood counts regularly throughout the study.
This study is currently recruiting participants at multiple medical centers across locations including Birmingham, Alabama, Duarte, California, and Atlanta, Georgia.
- 1Tests a new oral targeted cancer drug called HQP1351.
- 2Designed for patients whose previous leukemia treatments stopped working.
- 3Currently recruiting patients at multiple medical centers in the United States.
Related videos
2Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.